產品櫥窗
-
SP600125
|
產品型號：101-129-56-6 商品規格： |
 |
Selective inhibitor of c-Jun N-terminal kinase (JNK)
Synonyms: Anthra(1,9-cd)pyrazol-6(2H)-one, 1,9-Pyrazoloanthrone, Anthrapyrazolone, JNK Inhibitor II, SAPK Inhibitor II, NSC 75890, 1PMV
>99%
C14H8N2O
M.W. 220.23
SP600125 is an anthrapyrazolone inhibitor of JNK that competes with ATP to inhibit the phosphorylation of c-Jun. It prevents the activation of inflammatory genes such as COX-2, IL-2 IFN-γ and TNF-α. It prevents the activation of JNK after brain ischemia and may be effective in treatment of ischemic stroke.
Solubility: Prepare initial stock solutions in DMSO (soluble at 65 mg/mL) for in vitro use; solubility in ethanol or water is low.
SP600125 inhibited JNK, reduced the levels of c-Jun phosphorylation, prevented apoptosis in dopaminergic neurons, and partly reversed the loss of dopamine in MPTP-induced Parkinson's disease in C57BL/6N mice. Wang W., et al. "SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease." Neurosci. Res. 48: 195-202 (2004).
>99%
C14H8N2O
M.W. 220.23
SP600125 is an anthrapyrazolone inhibitor of JNK that competes with ATP to inhibit the phosphorylation of c-Jun. It prevents the activation of inflammatory genes such as COX-2, IL-2 IFN-γ and TNF-α. It prevents the activation of JNK after brain ischemia and may be effective in treatment of ischemic stroke.
Solubility: Prepare initial stock solutions in DMSO (soluble at 65 mg/mL) for in vitro use; solubility in ethanol or water is low.
SP600125 inhibited JNK, reduced the levels of c-Jun phosphorylation, prevented apoptosis in dopaminergic neurons, and partly reversed the loss of dopamine in MPTP-induced Parkinson's disease in C57BL/6N mice. Wang W., et al. "SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease." Neurosci. Res. 48: 195-202 (2004).
Store at -20 ºC